Inhibitor Therapeutics, Inc. (INTI) Operating cash flow 2016–2025
Inhibitor Therapeutics, Inc. (INTI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$3.2MFY2025 · since FY2016: -$3.8M → -$3.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.2M | +0.1% |
| FY2024 | -$3.2M | -19.7% |
| FY2023 | -$2.7M | -123.0% |
| FY2022 | $11.7M | +5426.2% |
| FY2021 | -$220,433 | +73.3% |
| FY2020 | -$825,357 | +69.5% |
| FY2019 | -$2.7M | +27.0% |
| FY2018 | -$3.7M | -27.3% |
| FY2017 | -$2.9M | +22.5% |
| FY2016 | -$3.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More INTI financial trends
INTI RevenueINTI Net incomeINTI Net marginINTI Gross profitINTI Gross marginINTI Operating incomeINTI Operating marginINTI Free cash flowINTI Capital expendituresINTI Return on equityINTI Stock buybacksINTI Dividends paidINTI Total assetsINTI Total liabilitiesINTI Shareholders’ equityINTI overview →